162 related articles for article (PubMed ID: 37889758)
1. Protocol for editing fibroblasts with in vitro transcribed Cas9 mRNA and profile off-target editing by optimized GUIDE-seq.
Li Z; Reint G; Haapaniemi EM
STAR Protoc; 2023 Dec; 4(4):102662. PubMed ID: 37889758
[TBL] [Abstract][Full Text] [Related]
2. Optimized protocol for gene editing in adipocytes using CRISPR-Cas9 technology.
Qiu Y; Ding Q
STAR Protoc; 2021 Mar; 2(1):100307. PubMed ID: 33554142
[TBL] [Abstract][Full Text] [Related]
3. Simplified CRISPR-Mediated DNA Editing in Multicellular Eukaryotes.
Kumar R; Tiwari K; Saudagar P
Methods Mol Biol; 2023; 2575():241-260. PubMed ID: 36301478
[TBL] [Abstract][Full Text] [Related]
4. Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity.
Basila M; Kelley ML; Smith AVB
PLoS One; 2017; 12(11):e0188593. PubMed ID: 29176845
[TBL] [Abstract][Full Text] [Related]
5. Amplification-free long-read sequencing reveals unforeseen CRISPR-Cas9 off-target activity.
Höijer I; Johansson J; Gudmundsson S; Chin CS; Bunikis I; Häggqvist S; Emmanouilidou A; Wilbe M; den Hoed M; Bondeson ML; Feuk L; Gyllensten U; Ameur A
Genome Biol; 2020 Dec; 21(1):290. PubMed ID: 33261648
[TBL] [Abstract][Full Text] [Related]
6. Heritable CRISPR-Cas9 editing of plant genomes using RNA virus vectors.
Uranga M; Aragonés V; Daròs JA; Pasin F
STAR Protoc; 2023 Mar; 4(1):102091. PubMed ID: 36853698
[TBL] [Abstract][Full Text] [Related]
7. Generation of zebrafish models by CRISPR /Cas9 genome editing.
Hruscha A; Schmid B
Methods Mol Biol; 2015; 1254():341-50. PubMed ID: 25431076
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of Cas9 mRNA and guide RNAs for editing of LGMN gene represses breast cancer cell metastasis.
Wang Y; Peng Y; Zi G; Chen J; Peng B
Sci Rep; 2024 Apr; 14(1):8095. PubMed ID: 38582932
[TBL] [Abstract][Full Text] [Related]
9. Determinants for Efficient Editing with Cas9-Mediated Recombineering in
Choudhury A; Fankhauser RG; Freed EF; Oh EJ; Morgenthaler AB; Bassalo MC; Copley SD; Kaar JL; Gill RT
ACS Synth Biol; 2020 May; 9(5):1083-1099. PubMed ID: 32298586
[TBL] [Abstract][Full Text] [Related]
10. Protocol for the saturation and multiplexing of genetic variants using CRISPR-Cas9.
Sahu S; Sullivan T; Southon E; Caylor D; Geh J; Sharan SK
STAR Protoc; 2023 Dec; 4(4):102702. PubMed ID: 37948185
[TBL] [Abstract][Full Text] [Related]
11. CRISPR deactivation in mammalian cells using photocleavable guide RNAs.
Zou RS; Liu Y; Ha T
STAR Protoc; 2021 Dec; 2(4):100909. PubMed ID: 34746867
[TBL] [Abstract][Full Text] [Related]
12. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
13. Optimizing sgRNA length to improve target specificity and efficiency for the GGTA1 gene using the CRISPR/Cas9 gene editing system.
Matson AW; Hosny N; Swanson ZA; Hering BJ; Burlak C
PLoS One; 2019; 14(12):e0226107. PubMed ID: 31821359
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of CRISPR/Cas9 Off-Target Activity in Hematopoietic Stem and Progenitor Cells.
Park SH; Lee CM; Bao G
Methods Mol Biol; 2022; 2429():281-306. PubMed ID: 35507169
[TBL] [Abstract][Full Text] [Related]
15. Targeted Genome Editing Using DNA-Free RNA-Guided Cas9 Ribonucleoprotein for CHO Cell Engineering.
Shin J; Lee N; Cho S; Cho BK
Methods Mol Biol; 2018; 1772():151-169. PubMed ID: 29754227
[TBL] [Abstract][Full Text] [Related]
16. CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs.
Coelho MA; De Braekeleer E; Firth M; Bista M; Lukasiak S; Cuomo ME; Taylor BJM
Nat Commun; 2020 Aug; 11(1):4132. PubMed ID: 32807781
[TBL] [Abstract][Full Text] [Related]
17. Optimization of genome editing through CRISPR-Cas9 engineering.
Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
[TBL] [Abstract][Full Text] [Related]
18. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
[TBL] [Abstract][Full Text] [Related]
19. Protocol for the electroporation of CRISPR-Cas for DNA and RNA targeting in Bos taurus zygotes.
Biase FH; Schettini G
STAR Protoc; 2024 Mar; 5(1):102940. PubMed ID: 38460133
[TBL] [Abstract][Full Text] [Related]
20. Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology.
Bai B; Myklebust JH; Wälchli S
Methods Mol Biol; 2020; 2115():445-454. PubMed ID: 32006416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
